Actavis-Valeant’s NDA of Metronidazole 1.3% vaginal gel gets US FDA approval
In April 2013, Valeant offered Actavis the rights to Metronidazole 1.3%, which provides a convenient, single-dose treatment for BV. BV is an infection caused by an imbalance in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.